Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience

BACKGROUND: Currently, the greatest challenge in hemophilia treatment is managing hemophilia patients with inhibitors. The two main bypassing agents that are used to treat hemophilia patients with inhibitors are activated prothrombin complex concentrates (APCC) and recombinant factor VIIa (rFVIIa)....

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Myung Hee, Park, Young Shil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894387/
https://www.ncbi.nlm.nih.gov/pubmed/24466553
http://dx.doi.org/10.5045/br.2013.48.4.282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894387/
https://www.ncbi.nlm.nih.gov/pubmed/24466553
http://dx.doi.org/10.5045/br.2013.48.4.282

Ejemplares similares